SOURCE: TheSUBWAY.com

October 12, 2006 09:35 ET

TheSUBWAY.com Posts Stock Pick List: Testing Results of Company's Product Are Statistically Significant!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.

WESTON, FL -- (MARKET WIRE) -- October 12, 2006 -- TheSUBWAY.com names the following stocks to its Stock Pick List: CepTor Corporation (OTCBB: CEPO), Rambus Inc. (NASDAQ: RMBS), Transmeta Corporation (NASDAQ: TMTA), Nabi Biopharmaceuticals (NASDAQ: NABI).

CepTor Corporation (OTCBB: CEPO), a biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, just announced that the results of Neurodur testing in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model, the standard animal model used for MS testing, were published in the Journal of Neuroimmunology. The data indicated that the reduction of clinical symptoms of MS in EAE mice treated with oral Neurodur were statistically significant.

The Chairman and CEO of CepTor, Bill Pursley, said, "The nice thing about the standard EAE model is that it allows you to directly address meaningful, clinical (functional) endpoints. These are exciting data in an important indication. This also demonstrates the breadth of our platform technology, cell targeted calpain inhibition, in one of several neurodegenerative diseases where the up regulation of calpain plays a key role in the pathophysiology of the disease."

Other stocks highlighted include Rambus Inc. (NASDAQ: RMBS): Stock Pick List, up 10% on 25 million shares, Transmeta Corporation (NASDAQ: TMTA): Stock Pick List, down 1% on 1 million shares, Nabi Biopharmaceuticals (NASDAQ: NABI): Stock Pick List, down 1% on 1 million shares.

"The central bank has left the benchmark short term lending rate at 5.25 percent, unchanged since late June, which marked the end to a two year rate hiking campaign. Before that, the Federal Reserve had raised rates after each of the 17 consecutive meetings over most of the last two years. Despite the rise in interest rates, the Dow has just recently surpassed its previous all-time high of 11,722.98 reached in January 2000." More is available at: http://www.thesubway.com.

TheSUBWAY.com's Daily Stock Updates:

TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.

All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated zero dollars for CEPO. CRG has not been compensated but could receive up to one hundred thousand dollars worth of cash or stock for CEPO. CRG intends to sell its shares. CRG has sold approximately zero CEPO shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Contact Information